$NVMI

Sagiv Sarit sold $456K of NVMI

Sagiv Sarit sold 820 shares of NOVA LTD. (NVMI) at an average of $556.46 ($536.52–$581.20, $0.46M total) across 2 trades over 2026-06-22 to 2026-06-23 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sagiv Sarit
Published Jun 24, 2026, 6:34 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 6:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NVMI
Neutral
medium confidence
Mentioned
$NVMI
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVMINeutralLow
01

Why it matters

The newest information is the director’s open-market sale details (dates, share count, price range, and total value) reported on 2026-06-24.

02

Market read

Traders may briefly reassess NVMI sentiment due to insider selling, but the 10b5-1 structure and modest transaction size likely limit follow-through.

03

What to watch

The filing does not disclose reasons for the sale; also, the post-transaction holdings (1,951 shares) suggest the director’s economic exposure remains relatively small, limiting signal strength.

Relevance 3/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-06-24)

Background

The article is an SEC Form 4 insider transaction disclosure for NOVA Ltd. (NVMI).

Company-level read

Ticker impact

$NVMINeutralMedium confidence
Context

SEC Form 4 shows director Sagiv Sarit sold $456.3K of NVMI shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing is primary-source and time-stamped, but it is a small-to-moderate dollar transaction and explicitly tied to a pre-arranged 10b5-1 plan, which often reflects routine liquidity rather than a new bearish thesis.

Market effects

No sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may be routine diversification/liquidity rather than a view on NVMI’s prospects.

Key entities

  • NVMI

    NOVA Ltd., issuer of the Form 4 insider transaction.

  • Sagiv Sarit

    Director of NVMI who sold shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVMIMedAI 8/10

Nova (NVMI) Just Blew Past $250M In Quarterly Sales

Nova (NVMI) reported Q2 2026 revenue of $255M, up 8% QoQ and 16% YoY, with GAAP net income of $75M and non-GAAP net income of $86.5M. GAAP EPS was $2.20, up from $2.04 QoQ and $2.14 YoY. Non-GAAP EPS was $2.51, up from $2.33 QoQ and $2.20 YoY. The company guided Q3 2026 revenue to $277M-$287M, GAAP EPS to $2.46-$2.61, and non-GAAP EPS to $2.70-$2.85. Gross margin declined to 56.5% from 57.7% QoQ and 57.8% YoY.

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$NVMIHigh

NOVA LTD. (NVMI): Financial results for Q2 2026

NOVA LTD. (NVMI) furnished an SEC Form 6-K — earnings release. Attached hereto and incorporated by way of reference herein is a press release issued by the Registrant and entitled: “Nova Reports Record Second Quarter 2026 Financial Results”. The GAAP financial statements tables included in the press release attached hereto are hereby incorpo

$TEVAMed

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.